{
    "clinical_study": {
        "@rank": "141370", 
        "arm_group": [
            {
                "arm_group_label": "MMF, Prednisone", 
                "arm_group_type": "Experimental", 
                "description": "Induction Phase (Months 1 through 6): Cyclophosphamide, 0.5 - 1 grams per square meter (g/m2) intravenous (i.v.) pulse once per month. Concurrent prednisone, 1 milligram per kilogram per day (mg/kg/day) gradually reduced to 10 mg/day orally (p.o.).\nMaintenance Phase (Months 7 through 12): mycophenolate mofetil (MMF), 1 g/day, p.o. twice daily (b.i.d.) for 2 weeks; 1.5 g/day p.o. three times daily (t.i.d.) for the next 2 weeks; 2 g/day p.o. b.i.d. for the remainder of the Maintenance Phase. Concurrent prednisone, as in the Induction Phase."
            }, 
            {
                "arm_group_label": "Maintenance Cyclophosphamide, Prednisone", 
                "arm_group_type": "Active Comparator", 
                "description": "Induction Phase (Months 1 through 6): Cyclophosphamide, 0.5 - 1 g/m2 i.v. pulse once per month. Concurrent prednisone, 1 mg/kg/day p.o. gradually reduced to 10 mg/day p.o.\nMaintenance Phase (Months 7 through 12): Cyclophosphamide, 0.5-1 g/m2 i.v. pulse every 3 months. Concurrent prednisone, as in the Induction Phase."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare the efficacy of CellCept (0.5-2g/day po) and cyclophosphamide\n      (0.5-1g/m2 quarterly) as maintenance treatment for patients with lupus nephritis. All\n      patients will receive induction treatment with cyclophosphamide (0.5-1g/m2 monthly) for 6\n      months, and will then be randomized to the maintenance phase of the study for a further 6\n      months, followed by 6 months of treatment-free follow-up. The anticipated time on study\n      treatment is 12 months."
        }, 
        "brief_title": "A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis", 
        "completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "condition": "Lupus Nephritis", 
        "condition_browse": {
            "mesh_term": [
                "Lupus Nephritis", 
                "Nephritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients >=18 years of age;\n\n          -  diagnosis of systemic lupus erythematosus and lupus nephritis (class III, IV or V).\n\n        Exclusion Criteria:\n\n          -  patients who have received cytotoxic drugs in previous 8 weeks;\n\n          -  systemic infections;\n\n          -  hepatitis B or C, or HIV."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081183", 
            "org_study_id": "ML18989"
        }, 
        "intervention": [
            {
                "arm_group_label": "MMF, Prednisone", 
                "description": "1 g/day, p.o. b.i.d. for 2 weeks; 1.5 g/day p.o. t.i.d. for the next 2 weeks; and 2 g/day p.o. b.i.d. for the remainder of the Maintenance Phase.", 
                "intervention_name": "Mycophenolate mofetil (MMF)", 
                "intervention_type": "Drug", 
                "other_name": "CellCept"
            }, 
            {
                "arm_group_label": "Maintenance Cyclophosphamide, Prednisone", 
                "description": "0.5-1 g/m2 i.v. pulse every 3 months", 
                "intervention_name": "Cyclophosphamide, Maintenance Phase", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MMF, Prednisone", 
                    "Maintenance Cyclophosphamide, Prednisone"
                ], 
                "description": "0.5 - 1 g/m2 i.v. pulse once per month", 
                "intervention_name": "Cyclophosphamide, Induction Phase", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MMF, Prednisone", 
                    "Maintenance Cyclophosphamide, Prednisone"
                ], 
                "description": "1 mg/kg p.o. once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Mycophenolate mofetil", 
                "Mycophenolic Acid", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Barquisimeto", 
                        "country": "Venezuela", 
                        "zip": "3005"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caracas", 
                        "country": "Venezuela", 
                        "zip": "1040"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Venezuela"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study to Evaluate the Efficacy of CellCept, Administered in a Sequential Treatment Scheme, in Delaying Progressive Renal Damage in Patients With Lupus Nephritis", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Venezuela: Instituto Nacional de Higiene \"Rafael Rangel\""
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Creatinine clearance", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Urinary protein", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Serum creatinine", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Serum albumin", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081183"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}